Is Pfizer (PFE) A Bargain Following Its Earnings Beat And 2026 Guidance Lift?

Pfizer (PFE) is back in focus after reporting a second quarter earnings beat, raising its 2026 revenue guidance midpoint by US$500 million, and highlighting new late stage data and regulatory milestones.

See our latest analysis for Pfizer.

The recent earnings beat and guidance lift have not yet translated into strong share price momentum for Pfizer. The stock’s 1 year total shareholder return of 8.22% contrasts with a weaker 3 year and 5 year total shareholder return record, which points to interest rebuilding from a lower base.

If you are comparing Pfizer with other healthcare opportunities, it can help to see what else is on investors’ radars right now through the 41 healthcare AI stocks

Pfizer now trades at a meaningful discount to both its own estimated fair value and analyst targets after this guidance lift. Is that a reasonable reflection of lingering market caution, or has sentiment moved too far for the fundamentals?

Most Popular Narrative: 14.2% Undervalued

Pfizer's most followed valuation narrative places fair value at $29.19 per share, above the recent $25.03 close, which frames the current discount as material and tied directly to long term pipeline expectations.

Robust expansion of Pfizer's late-stage pipeline, especially in oncology and rare diseases, with multiple high-potential launches and label expansions (e.g., Elrexfio in multiple myeloma, SV in non-small cell lung cancer, advanced ADC portfolio, and pipeline vaccines), stands to drive sustained long-term revenue and earnings growth by addressing rising global demand for innovative therapies as the population ages.

Read the complete narrative.

Want to see how this oncology and rare disease build out feeds into that $29.19 fair value for Pfizer? The core of the thesis is a reshaped revenue mix, higher margins and a richer earnings profile supported by a future valuation multiple that assumes investors will pay up for that shift.

Result: Fair Value of $29.19 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Pfizer’s story can change quickly if upcoming patent expiries bite harder than expected or if regulatory pricing moves weigh more heavily on margins and cash flow.

Find out about the key risks to this Pfizer narrative.

Another View: What Pfizer’s P/E Says

The main narrative frames Pfizer as 14.2% undervalued relative to a US$29.19 fair value. The P/E picture is more cautious. Pfizer trades at 19.1x earnings, above the US Pharmaceuticals average of 15.6x, but slightly below an estimated fair ratio of 20x.

That mix suggests the stock is cheaper than close peers on this metric, yet still priced at a premium to the wider industry. For you, the question is whether that premium reflects justified confidence in Pfizer's pipeline or leaves less room if expectations are not met.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this Pfizer story seems finely balanced between opportunity and caution, consider that a prompt to act quickly and test the numbers yourself using the 1 key reward and 4 important warning signs.

Looking for more investment ideas beyond Pfizer?

If Pfizer has sharpened your focus on quality, now is the time to broaden your watchlist and see what other stocks could fit your goals.

• Spot potential high payout opportunities by checking out the 7 dividend fortresses tailored for income focused investors.
• Hunt for quality at a discounted price range through the 53 high quality undervalued stocks that filters for fundamentals first.
• Strengthen the defensive side of your portfolio with the 82 resilient stocks with low risk scores so you do not overlook steadier options.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com